BOOK
Consultative Hematology, An Issue of Hematology/Oncology Clinics of North America - E-Book
Fred J. Schiffman | Anthony Mega
(2012)
Additional Information
Book Details
Abstract
Topics include: Why does my patient have leukocytosis?, Why Is My Patient Neutropenic?, Does My Patient with a Serum Monoclonal Spike have Multiple Myeloma?, DVT and Pulmonary Embolism, Why Does My Patient Have Lymphadenopathy/Splenomegaly?,and Why Does My Patient have Thrombocytopenia?
Table of Contents
Section Title | Page | Action | Price |
---|---|---|---|
Front Cover | Cover | ||
Hematology/Oncology Clinics of North America | i | ||
Copyright Page | ii | ||
Table of Contents | vii | ||
Contributors | iii | ||
Preface | xiii | ||
Chapter 1. Why is My Patient Anemic? | 205 | ||
WHAT IS ANEMIA? | 206 | ||
WHAT ARE THE DETERMINANTS OF HEMOGLOBIN CONCENTRATION? | 206 | ||
WHAT ARE THE CONSEQUENCES OF ANEMIA? | 209 | ||
SUMMARY | 209 | ||
WHY IS MY PATIENT ANEMIC? | 209 | ||
RED BLOOD CELL (RBC) LOSS OR DILUTION ANEMIA | 212 | ||
RED BLOOD CELL (RBC) PRODUCTION | 220 | ||
ANEMIA OF INFLAMMATION | 225 | ||
SUMMARY | 226 | ||
REFERENCES | 227 | ||
Chapter 2. Why Does My Patient Have Thrombocytopenia? | 231 | ||
PERTINENT HISTORY IN THE PATIENT WITH THROMBOCYTOPENIA | 231 | ||
PHYSICAL EXAMINATION | 231 | ||
ANCILLARY TESTS | 232 | ||
MECHANISMS OF THROMBOCYTOPENIA | 234 | ||
THROMBOCYTOPENIA IN THE INTERNAL MEDICINE PATIENT | 237 | ||
DRUG-INDUCED THROMBOCYTOPENIA | 239 | ||
POSTTRANSFUSION PURPURA | 242 | ||
THROMBOCYTOPENIA ASSOCIATED WITH INFECTIONS | 243 | ||
THROMBOCYTOPENIA IN THE INTENSIVE CARE UNIT | 243 | ||
THROMBOCYTOPENIA IN THE PATIENT WITH A HEMATOLOGIC MALIGNANCY | 246 | ||
THROMBOCYTOPENIA IN THE SOLID TUMOR PATIENT | 246 | ||
THROMBOCYTOPENIA IN THE STEM CELL AND SOLID ORGAN TRANSPLANT PATIENT | 247 | ||
SUMMARY | 247 | ||
REFERENCES | 247 | ||
Chapter 3. Why is My Patient Neutropenic? | 253 | ||
NEUTROPHIL OVERVIEW | 253 | ||
NEUTROPENIA | 253 | ||
DIAGNOSTIC WORKUP | 254 | ||
CAUSES | 255 | ||
ETHNIC VARIATION | 255 | ||
CONGENITAL NEUTROPENIA | 255 | ||
IMMUNE-RELATED NEUTROPENIA | 257 | ||
DRUGS | 260 | ||
INFECTIONS | 262 | ||
MALIGNANCY | 263 | ||
SUMMARY | 264 | ||
REFERENCES | 264 | ||
Chapter 4. Why Does My Patient Have Erythrocytosis? | 267 | ||
REGULATION OF ERYTHROPOIESIS | 268 | ||
RELATIVE POLYCYTHEMIAS | 269 | ||
ABSOLUTE POLYCYTHEMIAS | 269 | ||
SUMMARY | 278 | ||
REFERENCES | 279 | ||
Chapter 5. Why Does My Patient Have Thrombocytosis? | 285 | ||
REACTIVE THROMBOCYTOSIS (RT) | 285 | ||
ESSENTIAL THROMBOCYTOSIS (ET) AND MYELOPROLIFERATIVE STATES | 288 | ||
POLYCYTHEMIA VERA (PV) | 295 | ||
CHRONIC MYELOGENOUS LEUKEMIA (CML) | 295 | ||
PRIMARY MYELOFIBROSIS | 296 | ||
SUMMARY | 296 | ||
REFERENCES | 296 | ||
Chapter 6. Why Does My Patient Have Leukocytosis? | 303 | ||
WHITE BLOOD CELL (WBC) DEVELOPMENT | 303 | ||
DEVELOPMENT, MATURATION, AND SURVIVAL OF GRANULOCYTES | 304 | ||
DEVELOPMENT OF MONOCYTES | 304 | ||
LYMPHOCYTE DEVELOPMENT | 305 | ||
EVALUATION OF LEUKOCYTOSIS | 305 | ||
CLASSIFICATION OF LEUKOCYTOSIS | 305 | ||
DISTINGUISHING A PRIMARY HEMATOLOGIC DISORDER FROM A REACTIVE (SECONDARY) LEUKOCYTOSIS | 306 | ||
CAUSES OF SECONDARY LEUKOCYTOSIS | 306 | ||
HEMATOLOGIC MALIGNANCIES | 312 | ||
DIAGNOSTIC WORKUP OF LEUKOCYTOSIS | 315 | ||
SUMMARY | 317 | ||
REFERENCES | 317 | ||
Chapter 7. Why Is My Patient Bleeding Or Bruising? | 321 | ||
PATIENT HISTORY | 322 | ||
PHYSICAL EXAMINATION | 325 | ||
CLINICAL MANIFESTATIONS | 325 | ||
LABORATORY TESTING | 328 | ||
DIAGNOSTIC ALGORITHM AND DIFFERENTIAL DIAGNOSIS | 332 | ||
SUMMARY | 340 | ||
REFERENCES | 341 | ||
Chapter 8. Venous Thromboembolism Overview | 345 | ||
VENOUS THROMBOEMBOLISM (VTE): PRESENTATION | 347 | ||
VENOUS THROMBOEMBOLISM (VTE): DIAGNOSIS | 347 | ||
VENOUS THROMBOEMBOLISM (VTE): INITIAL TREATMENT | 348 | ||
DURATION OF ANTICOAGULATION THERAPY | 349 | ||
NEW ORAL ANTICOAGULANTS | 354 | ||
SUPERFICIAL VENOUS THROMBOSIS | 355 | ||
TRAVEL-RELATED VENOUS THROMBOSIS | 357 | ||
HYPERCOAGULABLE WORK-UP | 358 | ||
BRIDGING: ANTICOAGULATION BRIDGING FOR INVASIVE PROCEDURES | 359 | ||
SUMMARY | 361 | ||
REFERENCES | 362 | ||
Chapter 9. Does My Patient Have a Life- or Limb-Threatening Thrombocytopenia? | 369 | ||
DISEASE ENTITIES | 369 | ||
SUMMARY | 380 | ||
REFERENCES | 380 | ||
Chapter 10. Does My Patient with a Serum Monoclonal Spike have Multiple Myeloma? | 383 | ||
EPIDEMIOLOGY OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE | 383 | ||
DIAGNOSIS AND FOLLOW-UP OF PATIENTS WITH MONCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) | 385 | ||
RISK FACTORS FOR PROGRESSION AND STRATIFICATION MODELS FOR PATIENTS WITH MONCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) | 385 | ||
EPIDEMIOLOGY AND DIAGNOSTIC CRITERIA FOR SMOLDERING MULTIPLE MYELOMA (SMM), MULTIPLE MYELOMA (MM), AND PLASMA CELL (PC) DYSCRASIA VARIANTS | 386 | ||
CLINICAL PRESENTATION OF MULTIPLE MYELOMA (MM) | 387 | ||
SUSPECTING MULTIPLE MYELOMA (MM) IN A PATIENT WITH A MONOCLONAL SPIKE (M SPIKE) | 387 | ||
DIAGNOSTIC INVESTIGATIONS IN PATIENTS WHOSE MONCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) EVOLVES INTO MULTIPLE MYELOMA (MM) | 389 | ||
THE IMPORTANCE OF AN EARLY DIAGNOSIS OF MULTIPLE MYELOMA (MM) | 390 | ||
SUMMARY AND REMARKS | 390 | ||
REFERENCES | 390 | ||
Chapter 11. Why Does My Patient Have Lymphadenopathy or Splenomegaly? | 395 | ||
MECHANISMS OF LYMPHADENOPATHY | 395 | ||
MECHANISMS OF SPLENOMEGALY | 396 | ||
LOCATION OF LYMPHADENOPATHY | 396 | ||
EVALUATION OF LYMPHADENOPATHY | 400 | ||
LYMPH NODE CHARACTERISTICS | 402 | ||
LYMPH NODE SIZE AND BIOPSY CONSIDERATIONS | 402 | ||
SPLENOMEGALY | 402 | ||
WHEN SHOULD AN ENLARGED SPLEEN BE REMOVED | 405 | ||
SUMMARY | 405 | ||
REFERENCES | 405 | ||
Chapter 12. Special Hematologic Issues in the Pregnant Patient | 409 | ||
ANEMIA | 409 | ||
THROMBOCYTOPENIA | 413 | ||
PLATELET FUNCTION DISORDERS | 416 | ||
VON WILLEBRAND DISEASE (VWD) AND OTHER BLEEDING DISORDERS | 417 | ||
THROMBOPHILIA AND THROMBOEMBOLISM | 421 | ||
HEMATOLOGIC MALIGNANCIES | 427 | ||
SUMMARY | 428 | ||
REFERENCES | 428 | ||
Index | 433 |